Form D · Other Health Care

ABATTIS BIOCEUTICALS CORP

Vancouver, A1 · CIK 0001515768

Offering snapshot reported Apr 14, 2014 · SEC filing

Reported sold
$62.6K
Offering amount: $62.6K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 1, 2014
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 14, 2014Initial$62,554No comparison1SEC filing
Apr 3, 2014Initial$83,709No comparison6SEC filing
Mar 21, 2012Initial$20,014No comparison1SEC filing
Apr 6, 2011Amendment$29,727-$267,538vs Mar 17, 20113SEC filing
Mar 17, 2011Initial$297,265No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-215470

Source: Form D, filed Apr 14, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Yazan Al Homsi Director
Rene David Executive
Tim Fealey Director
Timothy Grzyb Director
Nathan Hansen Director, Executive
Robert Hedley Director
Robin B Hutchison Director
Gilbert Schneider Director
Travis S Schneider Director
Douglas J. Sorocco Director
Mike Withrow Director, Executive

Issuer details

Industry: Other Health Care (See others in industry)

Address:
Suite 1000 355 Burrard Street
Vancouver, A1, V6C 2G8